Solara Active Pharma Sciences Limited — Investor Meet, 29-07-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Solara Active Pharma Sciences delivered a strong Q1 FY26. Revenue grew 15% QoQ to ₹320 Cr, with gross margin at a healthy 54% and EBITDA at ₹57 Cr (up 13% QoQ). PAT reached a 12-quarter high of ₹10.5 Cr. Management views FY26 as a growth year, targeting 10% revenue and 15-20% EBITDA increase, focusing on profitable expansion and debt reduction. Ibuprofen contribution reduced to 30% of sales, shifting focus to derivatives. Net debt decreased by ₹143 Cr, aiming for ~2.7x Net Debt/EBITDA. The company is re-pivoting for sustainable, profitable growth.